124 related articles for article (PubMed ID: 8865893)
1. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin.
Ahsan N; Groff JA; Waybill MA
Adv Perit Dial; 1996; 12():161-6. PubMed ID: 8865893
[TBL] [Abstract][Full Text] [Related]
2. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
[TBL] [Abstract][Full Text] [Related]
3. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
Suh H; Wadhwa NK
Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
[TBL] [Abstract][Full Text] [Related]
4. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
Ahsan N
Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
Fishbane S; Lynn RI
Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
Raja R; Bloom E; Goldstein M; Johnson R
ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
[TBL] [Abstract][Full Text] [Related]
7. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
Ahsan N
Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
Ficheux M; Cuny P; Lecouf A; Ryckelynck JP; Hurault de Ligny B; Lobbedez T
Nephrol Ther; 2011 Dec; 7(7):558-61. PubMed ID: 21715234
[TBL] [Abstract][Full Text] [Related]
10. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
11. Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis.
Jonnalagadda V; Bloom EJ; Raja RM
Adv Perit Dial; 1997; 13():113-5. PubMed ID: 9360662
[TBL] [Abstract][Full Text] [Related]
12. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
[TBL] [Abstract][Full Text] [Related]
16. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
17. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
18. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
Johnson CA; Rosowski E; Zimmerman SW
Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
[TBL] [Abstract][Full Text] [Related]
19. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
[TBL] [Abstract][Full Text] [Related]
20. Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients.
Aguilera A; Bajo MA; Díez JJ; Ruiz-Caravaca ML; Vicenta Cuesta M; Alvarez V; Codoceo R; Selgas R
Adv Perit Dial; 2002; 18():200-5. PubMed ID: 12402619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]